A Randomized, Placebo Controlled, Evaluator-Blinded Study to Assess the Efficacy and Safety of NOX1416 in the Treatment of Chronic, Non-Healing, Diabetic Foot Ulcers
Latest Information Update: 19 Jan 2024
At a glance
- Drugs Nitric oxide (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- Acronyms NTCDU
- Sponsors NOxy Health Products
- 11 Jan 2024 Planned End Date changed from 24 May 2024 to 24 Nov 2024.
- 11 Jan 2024 Planned primary completion date changed from 10 Nov 2023 to 1 Sep 2024.
- 11 Jan 2024 Status changed from recruiting to suspended.